Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325027
- Eye Hospital, Wenzhou Medical College
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- moderate to severe dry eye syndrome
- tear film breakup time >0 second and ≤5 seconds,or schirmer test(no anaesthesia)≥2mm/5min and ≤5mm/5min
- corneal staining≥3 scores
Exclusion Criteria:
- allergic to any composition of the drugs under experiment
- previous use of anti-inflammatory drugs or immunosuppressive agent
- viral,bacterial or fungal infection of the eye
- eyelid anomaly
- glaucoma or high IOP
- significant meibomian gland dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: group 1
|
nonsteroid anti-inflammatory drops plus artificial tear substitute
Other Names:
|
|
EXPERIMENTAL: group 2
|
nonsteroid anti-inflammatory drops plus artificial tear substitute
Other Names:
|
|
EXPERIMENTAL: group 3
|
corticosteroids plus artificial tear substitute
Other Names:
|
|
OTHER: group 4
|
artificial tear substitute alone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
tear osmolarity
Time Frame: Day 0, Day 14
|
Day 0, Day 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
corneal staining
Time Frame: 0 day,7th day and 14th day after treatment
|
0 day,7th day and 14th day after treatment
|
|
Schirmer test(without anaesthesia)
Time Frame: 0 day,7th day,14th day after treatment
|
0 day,7th day,14th day after treatment
|
|
tear film breakup time(TBUT)
Time Frame: 0 day,7th day and 14th day after treatment
|
0 day,7th day and 14th day after treatment
|
|
meibomian gland function
Time Frame: 0 day,7th day and 14th day after treatment
|
0 day,7th day and 14th day after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Eye Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Allergic Agents
- Pharmaceutical Solutions
- Ophthalmic Solutions
- Anti-Inflammatory Agents
- Lubricant Eye Drops
- Fluorometholone
Other Study ID Numbers
Other Study ID Numbers
- Xzhou
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.